Ani Pharmaceuticals (ANIP) EPS (Basic) (2010 - 2026)

Ani Pharmaceuticals has disclosed EPS (Basic) across 17 years of filings, most recently posting $1.31 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $1.31, up 87.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.11 (up 426.19% YoY), and the FY2025 annual result was $3.5, up 436.54% from the prior year.
• EPS (Basic) came in at $1.31 for Q1 2026 at Ani Pharmaceuticals, up from $1.24 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $1.31 in Q1 2026 to a low of -$1.27 in Q1 2022.
• The 5-year median for EPS (Basic) is $0.06 (2023), against an average of $0.09.
• Across the five-year window, EPS (Basic) plunged 12800.0% in 2022 and surged 1300.0% in 2024, its largest moves.
• Ani Pharmaceuticals' EPS (Basic) stood at -$0.29 in 2022, then jumped by 106.9% to $0.02 in 2023, then slumped by 2850.0% to -$0.55 in 2024, then jumped by 325.45% to $1.24 in 2025, then grew by 5.65% to $1.31 in 2026.
• The last three EPS (Basic) figures came in at $1.31 (Q1 2026), $1.24 (Q4 2025), and $1.19 (Q3 2025), per Business Quant data.